Mittal, Karuna
Cooper, Garrett W.
Lee, Benjamin P. http://orcid.org/0000-0002-6937-2211
Su, Yongdong http://orcid.org/0000-0002-2092-8872
Skinner, Katie T.
Shim, Jenny http://orcid.org/0000-0002-6717-2347
Jonus, Hunter C.
Kim, Won Jun
Doshi, Mihir
Almanza, Diego http://orcid.org/0000-0003-1222-9366
Kynnap, Bryan D.
Christie, Amanda L.
Yang, Xiaoping http://orcid.org/0000-0002-6811-4915
Cowley, Glenn S. http://orcid.org/0000-0002-0526-0616
Leeper, Brittaney A. http://orcid.org/0000-0001-8807-2954
Morton, Christopher L.
Dwivedi, Bhakti
Lawrence, Taylor
Rupji, Manali http://orcid.org/0000-0002-0520-1624
Keskula, Paula
Meyer, Stephanie
Clinton, Catherine M.
Bhasin, Manoj http://orcid.org/0000-0001-5172-420X
Crompton, Brian D. http://orcid.org/0000-0001-9404-6621
Tseng, Yuen-Yi
Boehm, Jesse S.
Ligon, Keith L. http://orcid.org/0000-0002-7733-600X
Root, David E. http://orcid.org/0000-0001-5122-861X
Murphy, Andrew J. http://orcid.org/0000-0001-6747-0355
Weinstock, David M. http://orcid.org/0000-0002-8724-3907
Gokhale, Prafulla C. http://orcid.org/0000-0002-1974-5921
Spangle, Jennifer M.
Rivera, Miguel N. http://orcid.org/0000-0002-3636-2113
Mullen, Elizabeth A. http://orcid.org/0000-0002-6704-0002
Stegmaier, Kimberly http://orcid.org/0000-0003-0218-7895
Goldsmith, Kelly C. http://orcid.org/0000-0001-8672-2298
Hahn, William C. http://orcid.org/0000-0003-2840-9791
Hong, Andrew L. http://orcid.org/0000-0003-0374-1667
Funding for this research was provided by:
American Cancer Society (MRSG-18-202-01)
CureSearch for Children’s Cancer (328545)
Rally Foundation (21IN12, 22IC37)
U.S. Department of Defense (W81XWH1910281)
Article History
Received: 17 March 2022
Accepted: 3 April 2024
First Online: 8 April 2024
Competing interests
: The authors declare the following competing financial interests. K.M. is currently employed at PreludeDx. A.L.C. is currently an employee of AstraZeneca. G.C. is currently an employee of Johnson & Johnson. D.M.W. is currently an employee of Merck and has research support from Daiichi Sankyo, Abcuro, Verastem, Secura, and is on the Advisory Board or has equity in Ajax, Travera, AstraZeneca, Bantam. K.S. receives grant funding from Novartis and KronosBio, consults for and has stock options in Auron Therapeutics and has served as an advisor for KronosBio and AstraZeneca. D.E.R. receives research funding from members of the Functional Genomics Consortium (Abbvie, BMS, Jannsen, Merck, Vir), and is a director of Addgene, Inc. W.C.H. is a consultant for ThermoFisher, Solasta Ventures, MPM Capital, KSQ Therapeutics, Tyra Biosciences, Jubilant Therapeutics, RAPPTA Therapeutics, Function Oncology, Frontier Medicines, Hexagon Biosciences, Serinus Biosciences, Kestral Therapeutics and Calyx. The remaining authors declare no competing interests.